Yasminelle®: A new low-dose combined oral contraceptive containing drospirenone

Women's Health

Volumn 2, Issue 4, 2006, Pages 551-559

  Sillem, Martin ^a  

^a DRK Krankenhaus Neuwied   (Germany)

Author keywords

Contraception; Cycle control; Drospirenone; Efficacy; Ethinylestradiol; Satisfaction; Yasmin ; Yasminelle

Indexed keywords

DESOGESTREL PLUS ETHINYLESTRADIOL; DIANE; DROSPIRENONE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTIMATE; GESTAGEN; MINERALOCORTICOID; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; YASMINELLE;

ABDOMINAL PAIN; ACNE; AREA UNDER THE CURVE; BODY WEIGHT DISORDER; BREAST AUGMENTATION; CLINICAL TRIAL; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; DYSMENORRHEA; ENCAPSULATION; HEADACHE; HUMAN; LIBIDO DISORDER; LOW DRUG DOSE; MASTALGIA; MENSTRUATION; MENTAL INSTABILITY; NONHUMAN; ORAL CONTRACEPTION; OVULATION INHIBITION; PHARMACODYNAMICS; REVIEW; SEBORRHEA; VAGINA CANDIDIASIS; VENOUS THROMBOEMBOLISM; WATER RETENTION; WEIGHT GAIN;

EID: 33745609217     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.4.551     Document Type: Review

References (40)

1. Trussell J: Contraceptive efficacy. In: Contraceptive Technology (17th Revised Edition). Hatcher RA, Trussell J, Stewart F et al. (Eds). Irvington Publishers, NY, USA, 779-844 (1998).
2. Shvarts S, Besinque K, Atkinson R, Gill M: New advances in contraception. Insights 11-22 (2002).
3. Skouby SO: Contraceptive use and behavior in tAe 21st century: a comprehensive study across five European countries. Eur. J. Contracept. Reprod. Health Care 9(2), 57-68 (2004).
4. Rosenberg MJ, Waugh MS: Oral cAntraceptive discontinuation: a prospective evaluation of frequency and reasons. Am. J. Obstet. Gynecol. 179, 577-582 (1998).
5. Rosenberg MJ, Waugh MS, Long S: Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. J. Reprod. Med. 40(5), 355-360 (1995).
6. Boschitsch E: Tomen's well-being: the non-contraceptive benefits of Yasmin®. Gynaecology Forum 7(1), 23-26 (2002).
7. KrattenmPcher R: Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 62 (1), 29-38 (2000).
8. Huber J, Foidart JM, Wuttke W et al.: Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur. J. Contracept. Reprod. Health Care 5(1), 25-34 (2000).
9. Parsey KS, Pong A: An open-label, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception 61(2), 105-111 (2000).
10. Foidart J-M, Wuttke W, Bouw GM, Gerlinger C, Heithecker R: A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. Eur. J. Contracept. Reprod. Health Care 5(2), 124-134 (2000).
11. Thorneycroft IH, Gollnick H, Schellschmidt I: Superiority of a combined oral contraceptive containing drospirenone to a triphaisc preparation containing norgestimate in acne treatment. Cutis 74, 123-130 (2004).
12. van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R: The effect of 2 combined oral contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea. Cutis 69 (Suppl. 4), 2-15 (2002).
13. Goldberg A, Darney P: Female contraception. In: Principles and Practice of Endocrinology and Metabolism. Becker K (Ed.). Lippincott Williams & Wilkins, PA, USA, 1022-1033 (2001).
14. The ESHRE Capri Workshop Group: Noncontraceptive health benefits of combined oral contraception. Hum. Reprod. Update 11(5), 513-525 (2005).
15. Rosenbaum P, Schmidt W, Helmerhorst FM et al: Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol. Eur. J. Contracept. Reprod. Health Care 5(1), 16-24 (2000).
16. Lüdicke F, Johannisson E, Helmerhorst FM et al.: Effect of a combined oral contraceptive containing 3 mg of drospirenone and 30 μg of ethinyl estradiol on the human endometrium. Fertil. Steril. 76(1), 102-107 (2001).
17. Oelkers W, Berger V, Bolik A et al.: Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: Effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J. Clin. Endocrinol. Metab. 73(4), 837-842 (1991).
18. Oelkers W, Helmerhorst FM, Wuttke W, Heithecker R: Effect of an oral contraceptive containing drospirenone on the renin-angiotensin-aldosterone system in healthy female volunteers. Gynecol Endocrinol. 14(3), 204-213 (2000).
19. Schunkert H, Danser AH, Hense HW et al.: Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 95(1), 39-45 (1997).
20. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R: Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J. Clin. Endoctrinol. Metab. 80(6), 1816-1821 (1995).
21. Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH: The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 54(4), 243-251 (1996).
22. Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E: Drospirenone: A novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann. NY Acad. Sci. 761, 311-335 (1995).
23. Kuhnz W, Blode H, Zimmermann H: Pharmacokinetics of exogenous natural and synthetic estrogens and antiestrogens. In: Handbook of Experimental Pharmacalogy. Oettel M, Schillinger E (Eds). Springer-Verlag, Berlin, Germany, 281-291 (1999).
24. Nakamich IN, Blode H, Marr J: The pharmacokinetics of a new low-dose combined oral contraceptive containing ethinylestradiol 20mcg and drospirenone 3mg in Caucasian and Japanese women. 12th World Congress of Gynecological Endocrinology. International Society of Gynecological Endocrinology. March 2-5, Florence. Italy (2006).
25. Blode H: Pharmacokinetics of drospirenone. Gynaecology forum 7(1), 18-22 (2002).
26. Blode H, Wuttke W, Loock W, Roll G, Heithecker R: A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur. J. Contracept. Reprod. Health Care 5(4), 256-264 (2000).
27. Cibula D, Karck U, Weidenhammer HG et al.: Efficacy and safety of a low-dose 21-day combined oral contraceptive containing ethinylestradiol 20 μg and drospirenone 3 mg. Clin. Drug Invest. 26(3), 143-150 (2006).
28. Gruber DM, Huber JC, Benedetto Melis G et al.: A comparison of the cycle control, safety and efficacy profile of ethinylestradiol 20 μg and drospirenone 3mg with a 21 day regimen of ethinylestradiol 20 μg and desogestrel 150 μg. Treat. Endocrinol. 5(2), 115-121 (2006).
29. Archer DF, Maheux R, DelConte A: Efficacy and safety of a low-dose monophasic combination oral contraceptive containing 100 μg levonorgestrel and 20 μg ethinyl estradiol (Alesse®). Am. J. Obstet. Gynecol. 181(5 Pt 2), S39-S44 (1999).
30. Endrikat J, Dusterberg B, Ruebig A, Gerlinger C, Strowitzki T: Comparison of efficacy, cycle control, and tolerability of two low-dose oral contraceptives in a multicenter clinical study. Contraception 60(5), 269-274 (1999).
31. Crosignani PG, La Vecchia C: Concordant and discordant effects on cardiovascular risks exerted by oestrogen and progestogen in women using oral contraception and hormone replacement therapy. ESHRE Capri Workshop Group. Hum. Reprod. Update 5(6), 681-687 (1999).
32. Heinemann LA, Dinger J: Safety of a new oral contraceptive containing drospirenone. Drug Saf. 27(13), 1001-1018 (2004).
33. Gestodene Study Group 322: The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestradiol 15 microg. Eur. J. Contracept. Reprod. Health Care 4 (Suppl. 2), 9-15 (1999).
34. Sulak PJ, Scow RD, Preece C, Riggs MW, Kuehl TJ: Hormone withdrawal symptoms in oral contraceptive users. Obstet. Gynecol. 95(2), 261-266 (2000).
35. Sillem M, Schneidereit R, Heithecker R, Mueck AO: Use of an oral contraceptive containing drospirenone in an extended regimen. Eur. J. Contracept. Reprod. Health Care 8(3), 162-169 (2003).
36. Sulak PJ, Cressman BE, Waldrop E, Holleman S, Kuehl TJ: Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet. Gynecol. 89(2), 179-183 (1997).
37. Bachmann G, Sulak PJ, Sampson-Landers C, Benda N, Marr J: Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone. Contraception 70(3), 191-198 (2004).
38. Yonkers K.A, Brown C, Pearlstein TB et al.: Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. Obstet Gynecol. 106(3), 492-501 (2005).
39. Pearistein TB, Bachmann GA, Zacur HA, Yonkers KA: Treatment of premenstrual dysphoric disorder with a new drospirenonecontaining oral contraceptive formulation. Contraception 72(6), 414-421 (2005).
40. Anderson FD, Hait H: A multicenter, randomized study of an extended cycle oral contraceptive. Contraception 68, 89-96 (2003).